172 results about "Histocytochemistry" patented technology

Presented herein are systems, methods, and non-transient computer readable media for determining predicted response scores of subjects. A computing system may identify a first feature set for a first subject to be administered with immunotherapy to address a condition. The first feature set may include one or more of: (i) a first radiological feature identified in a tomogram of a section associated with the condition in the first subject, (ii) a first immunohistochemistry (IHC) feature derived from an image of a sample associated with the first subject, and (iii) a first genomic feature obtained from gene sequencing of the first subject for genes associated with the condition. The computing system may apply the first feature set to a model. The computing system may determine, from applying the first feature set to the model, a predicted score identifying a response to the immunotherapy to be administered to the first subject.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

A deep learning-based digital / virtual staining method and system enables the creation of digitally / virtually-stained microscopic images from label or stain-free samples. In one embodiment, the method of generates digitally / virtually-stained microscope images of label-free or unstained samples using fluorescence lifetime (FLIM) image(s) of the sample(s) using a fluorescence microscope. In another embodiment, a digital / virtual autofocusing method is provided that uses machine learning to generate a microscope image with improved focus using a trained, deep neural network. In another embodiment, a trained deep neural network generates digitally / virtually stained microscopic images of a label-free or unstained sample obtained with a microscope having multiple different stains. The multiple stains in the output image or sub-regions thereof are substantially equivalent to the corresponding microscopic images or image sub-regions of the same sample that has been histochemically stained.

The invention provides an application of narirutin in preparation of a medicine for preventing and / or treating osteoclast of inflammatory arthritis, relates to the technical field of biomedicine, and adopts a collagen-induced mouse arthritis model to observe the treatment effect of the narirutin on the osteoclast of the inflammatory arthritis. The arthritis activity degree of the mouse is analyzed through general claw photographing, thickness measurement, near-infrared temperature measurement and a claw imprinting experiment, three-dimensional reconstruction and bone trabecula analysis are carried out on local joints and the whole body bone mass of the mouse through micro-CT scanning, and Hamp is applied; e, dyeing and Famp; through histological staining analysis such as O staining and TRAP staining, in combination with immunohistochemical staining and the like, the narirutin is proved to play a role in treating inflammatory arthritis, inhibit macrophage pro-inflammatory M1 type polarization, relieve the inflammation level, improve the bone mass of local joints and the whole body, and further improve bone destruction in inflammatory arthritis diseases. The narirutin provides a new way for medicine prevention and treatment of inflammatory arthritis.

The utility model relates to a staining kit, in particular to an immunohistochemical staining kit. The kit comprises a storage box, a clamping plate is arranged in the storage box, a plurality of clamping grooves are evenly formed in the clamping plate, a kit body is arranged in the clamping grooves, a plurality of placing grooves are evenly formed in the kit body around the circle center, reagent bags are arranged in the placing grooves, and different reagents are stored in the reagent bags; a sliding groove is formed in the inner wall of the top end of the kit close to the placing groove, and a cutting assembly is slidably connected into the sliding groove and used for cutting the reagent capsule. According to the kit storage box, a combined structure of the clamping grooves and the kits is designed, and the kits are placed in the clamping grooves, so that the kits are orderly arranged in the storage box and are convenient to manage and take, the efficiency of an experiment preparation stage is favorably improved, and disorder and loss of the kits are reduced; the reagent bag body can be stably placed in the placing groove, stability and safety of the reagent in the storage process are guaranteed, meanwhile, the reagent bag body can rapidly release the reagent into the kit after being cut through the arrangement of the liquid inlet, automatic feeding of the reagent is achieved, and complexity and errors of manual operation are avoided.

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.

An oncological foundation model is trained with broad, multimodal data to make predictions concerning a variety of different types of cancers. For example, the foundation model may make use of medical images drawn from radiology and pathology, as well as immunohistochemistry data; the presence or absence of biomarkers for particular diagnoses; patient history data; patient demographic data; and other forms of medical data. When using medical images, whole medical images as well as feature sets derived from the medical images may be used. The foundation model may have both causal predictive abilities as well as generative abilities.

Techniques for using combination stain types for machine learning models for digital pathology are described herein. In an example, a system accesses a first image of a sample comprising an immunohistochemistry (IHC) stain for a biomarker. The system accesses a second image of the sample comprising a hematoxylin and eosin (H&E) stain for nuclei. The system can segment tissue regions in the one or more first images and the second image, partitions the tissue regions in the one or more first images and the second image, and extracts features from the set of tiles using a feature extractor. The system can generate, by a machine-learning model, an output classification indicating a first phenotype based on the features extracted from the set of tiles. The machine-learning model can include one or more classifiers and an aggregation model that provides an aggregated output for the set of tiles.

A system and method for performing virtual birefringence imaging and virtual staining (e.g., Congo red) of label-free human tissue is disclosed to show that a single trained neural network can rapidly transform autofluorescence images of label-free tissue into brightfield and polarized microscopy images, matching their histochemically-stained versions. Blind testing with quantitative metrics and pathologist evaluations on cardiac tissue showed that the virtually stained polarization and brightfield images highlight amyloid patterns in a consistent manner, mitigating challenges due to variations in chemical staining quality and manual imaging processes in the clinical workflow.

The invention discloses a fluorescence coding probe and a single cell immunoblotting method. The nucleic acid tag comprises oligonucleotide chains f1, f2... fn, n is greater than 2, each oligonucleotide chain contains a fluorophore and a quenching group, partial sequences of the next oligonucleotide chain and the previous oligonucleotide chain are complementarily paired, and the quenching group of the next oligonucleotide chain quenches the fluorophore of the previous oligonucleotide chain. Also disclosed is a quenching tag comprising a complementary strand capable of complementary pairing with an oligonucleotide strand in a nucleic acid tag. The invention discloses a fluorescent coding probe comprising a nucleic acid label, a preparation method of the fluorescent coding probe and application of the fluorescent coding probe in a multi-target single-cell immunoblotting technology, an immunofluorescence technology and an immunohistochemical staining technology. According to the fluorescence-coded multi-target single-cell immunoblotting method disclosed by the invention, multi-target protein detection can be carried out by utilizing limited fluorescence channels, the signal loss is small, and the expansibility is high.

The present invention relates to the field of medical testing. Specifically, the present invention provides a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer and its application. For the first time, the present invention systematically analyzed the content and spatial distribution map of the microenvironment components of CLDN18.2-positive gastric cancer tissue samples by integrating multiple fluorescent immunohistochemistry detection and whole-slice digital imaging quantitative analysis methods. Through multidimensional evaluation of the tumor microenvironment under the treatment background of CT041, a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer was established for the first time, which enables accurate screening of beneficiary populations and risk stratification before treatment, guides treatment selection, and improves treatment efficacy.

The invention relates to the technical field of medical imaging, in particular to a breast cancer tissue HER2 automatic scoring method and device based on a characteristic curve, and the method comprises the steps: carrying out the reading operation of a full-slice image of immunohistochemical staining; extracting a target region of interest of the full slice image; slicing and screening the target region of interest to obtain a plurality of image slices; calculating a percentage-saturation characteristic curve of each image slice, and extracting characteristic information of the percentage-saturation characteristic curve; based on the feature information of the percentage-saturation feature curve, performing preliminary HER2 scoring on each image slice in combination with a rule base and a logistic regression classification algorithm; and integrating the scoring results of the image slices, and outputting a final HER2 score and a characteristic curve visualization graph. According to the method, the feature curve is combined with the rule base and the logistic regression classification algorithm, so that the objectivity of HER2 scoring is improved, and the problems of subjectivity and low efficiency of manual evaluation are reduced.

Microglial spatial heterogeneity remains a crucial yet poorly studied question in light of potential cell-directed therapies for Alzheimer`s disease (AD). Little is known about the dynamics of spatially distinct microglia states, which are either adjacent or non-associated with the plaque site, and their selective contributions to neurodegeneration in vivo. So far, research has essentially focused on pathology-associated microglia. Here, we combined novel multicolor fluorescence fate mapping, single-cell transcriptional analysis, epigenetic profiling, advanced immunohistochemistry and computational modelling to comprehensively characterize the relation of plaque-associated and non-plaque- associated microglia during neurodegeneration. This approach enabled us to identify and characterize non-plaque-associated microglia as a unique and highly dynamic microglial state in a mouse model of AD. Non-plaque-associated microglia modulate network expansion, quickly adapt to environmental cues and their transition to plaque-associated microglia can be specifically modulated during disease, contrary to their reputation as a passive bystander subpopulation. This description of the dynamics of spatially segregated microglial states and their distinct molecular features may therefore open promising new avenues for state-specific therapeutic interventions during neurodegeneration.

The invention belongs to the technical field of immunohistochemical detection, and discloses a modified composite sealing buffer solution as well as a preparation method and detection application thereof. The modified composite blocking buffer solution comprises a basic buffer system, a composite blocking agent, a nonionic detergent, an endogenous interferent blocking agent and an antibody stabilizer, wherein the basic buffer system provides a stable pH environment and ionic strength; the composite sealing agent firstly occupies a shielding site, and the background is lowered; the nonionic detergent destroys hydrophobic interaction, effectively elute and loosen adsorbed molecules, and promote dissolution of components with relatively strong hydrophobicity; the endogenous interferent blocker can be combined with a receptor firstly, so that non-specific combination of an antibody and the receptor is blocked, and the problem of specific background is solved; the antibody stabilizer can protect the activity of the detection reagent and maintain the stability, and the obtained modified composite sealing buffer solution and the kit thereof have the advantages of multiple cooperative sealing mechanisms, prospective blocking of endogenous interference, improvement of the stability, compatibility and high efficiency of the antibody and the like.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.

The present disclosure provides antibodies, including but not limited to monoclonal antibodies, capable of specifically binding the human PAX8 protein. Also provided are nucleic acids encoding the anti-PAX8 antibodies described herein, as well as expression vectors comprising these nucleic acids, host cells transformed with the expression vectors comprising the nucleic acids encoding the anti-PAX8 antibodies, and methods of making the antibodies. The anti-PAX8 antibodies described herein are useful for immunohistochemical detection of human PAX8 protein in tissue samples.

The invention discloses application of jellyfish and snow rabbits in inhibition of ERK phosphorylation level and MAPK pathway and an evaluation method of the jellyfish and snow rabbits, and relates to the technical field of biological medicines.The method comprises the following steps that 1, a treated jellyfish and snow rabbits breast cancer cell group and a control breast cancer cell group are established; and step 2, respectively dividing the two groups of samples in the step 1 into two parts, fixing one part in paraformaldehyde with the mass concentration of 10%, treating, embedding in paraffin for immunohistochemical analysis, and quickly freezing the other part for transcriptomics analysis and the like. According to the invention, UPLC-MS is adopted to determine the main components of SMM, the influence of SMM on breast cancer (BC) is evaluated through in-vivo experiments, in order to deeply clarify the mechanism, network pharmacology and transcriptomics analysis are integrated, finally, immunohistochemistry (IHC) is adopted to verify and explore the exact breast cancer resisting mechanism of SMM, and a scientific basis is provided for potential clinical application of SMM.

The invention relates to a confining liquid and method for reducing background signals in immunohistochemical detection, and belongs to the technical field of immunodetection, and the confining liquid comprises whey protein and an anionic surfactant. By utilizing the confining liquid provided by the invention, background signals generated on a glass slide can be reduced or even eliminated, and the convenience and accuracy of interpretation of an immunohistochemical detection result are improved.

A system and method of categorizing protein expression in biological cells may include receiving a Whole Slide Image (WSI) of an Immunohistochemistry (IHC) assay of cells, stained with two or more color-specific markers, of two or more respective proteins, and applying a stain separation algorithm on the WSI image, to obtain two or more single¬ channel marker images. Based on the two or more marker images, embodiments may generate an enhanced color image, representing expression of the two or more proteins in the assay, and prompt a user to assign at least one label to at least one respective location in the enhanced color image. Embodiments may then use the at least one label as supervisory information, to train a machine-learning (ML)-based classification model, to classify at least one cell -representative location according to categories of expression of the at least two proteins.

The application relates to the field of immunohistochemical staining, in particular to a DAB buffer and a DAB staining solution kit for DAB color development. The application discloses a DAB buffer for DAB color development, and the main components are hydrogen peroxide, nonylphenol polyoxyethylene ether, magnesium sulfate and trisodium citrate. The metal ions in the DAB buffer can enhance the electron transfer speed between DAB and hydrogen peroxide, and improve the color development sensitivity. The nonylphenol polyoxyethylene ether can stabilize the hydrogen peroxide, so that the hydrogen peroxide can be stored for a longer time and the cost is saved. The application further discloses a DAB staining solution kit, which comprises a blocking agent, a reaction enhancer, an enzyme-labeled polymer IgG, a DAB concentrated solution, a DAB buffer and hematoxylin, and the above-mentioned DAB buffer for DAB color development. The DAB staining solution kit of the application can improve the detection sensitivity of immunohistochemical staining, and can also improve the storage stability of the DAB color development solution and reduce the cost.

The invention relates to application of a TM4SF1 gene and an inhibitor of the TM4SF1 gene in detection of PVR or preparation of a medicine for treating the PVR, and belongs to the field of biological medicine. PVRMs samples are sequenced, one fibroblast subtype is found to be derived from differentiation of RPE cells through cell subset clustering analysis and quasi-timing analysis, and the TM4SF1 gene participates in regulation and control of the process. The method comprises the following steps: constructing a short interference oligonucleotide capable of silencing a TM4SF1 gene to obtain a TM4SF1 silencing RNA (Ribonucleic Acid); through a Transwell migration experiment, it is found that after the TM4SF1 gene is silenced, fibrosis change caused by TGF-beta 1 can be inhibited; immunohistochemistry and immunocytochemistry show that after the TM4SF1 is silenced, the fibrosis change caused by the TGF-beta 1 can be inhibited through the (TM4SF1-siRNA). The method provided by the invention shows that the TM4SF1 gene expression level can be used as a basis for detecting the proliferative vitretinopathy; the method provided by the invention also shows that the effect of treating proliferative vitretinopathy can be achieved by inhibiting the expression of the TM4SF1 gene.

Applicants have developed an amplification system and methodology for IHC and ISH staining that utilizes “click chemistry” to covalently bind reporter molecules to tissue.

The invention also related to a device and a computer-implemented method for generating n virtual Immunohistochemical (IHC) stain images from one Hematoxylin and Eosin (H&E) stain image, using the IHC machine learning system obtained thanks to the device for training.

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

The application discloses a marker combination for predicting the curative effect of liposarcoma based on immunohistochemistry, a screening method and a prediction model thereof and a construction method thereof. The application analyzes the tissue phenotype characteristics of a liposarcoma patient by using an immunohistochemistry technology, combines transcriptomic data, screens a suitable marker combination NCF1, CD27, LST1, CD8A and AOAH based on Lasso-logistic regression, and establishes a more accurate immunotherapy curative effect prediction model for the liposarcoma patient.

The present disclosure provides antibodies that specifically bind to protein tyrosine kinase 7 (PTK7), and methods of using such antibodies. In some cases, the PTK7 antibodies are used in an immunohistochemistry (IHC) assay, which can detect the presence of cells expressing PTK7 in a tissue from a patient.

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.